Testing effectiveness (Phase 2)UnknownNCT03614858
What this trial is testing
CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
Who this might be right for
Leukemia, B-cell
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd 20